Tozer TN, Bois FY, Hauck WW, Chen ML, Williams RL. Absorption rate vs. exposure: which is more useful for bioequivalence testing? Pharm Res. 1996;13:453–6. https://doi.org/10.1023/a:1016061013606.

Article  CAS  PubMed  Google Scholar 

Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657–80. https://doi.org/10.1007/bf01068419.

Article  CAS  PubMed  Google Scholar 

Titus VR, Sanghavi M, Jamei M, Rostami-Hodjegan A. From hypothesis to forecasting: the impact of within-subject variability of gastro-intestinal physiology in relation to likelihood of sex-dependent outcome of bioequivalence. Eur J Pharm Sci. 2025;212:107213. https://doi.org/10.1016/j.ejps.2025.107213.

Article  CAS  PubMed  Google Scholar 

Bego M, Patel N, Cristofoletti R, Rostami-Hodjegan A. Proof of concept in assignment of within-subject variability during virtual bioequivalence studies: propagation of intra-subject variation in gastrointestinal physiology using physiologically based pharmacokinetic modeling. AAPS J. 2022;24:21. https://doi.org/10.1208/s12248-021-00672-z.

Article  PubMed  PubMed Central  Google Scholar 

Purohit V, Sagawa K, Hsu HJ, Kushner J, Dowty ME, Tse S, et al. Integrating clinical variability into PBPK models for virtual bioequivalence of single and multiple doses of Tofacitinib modified-release dosage form. Clin Pharmacol Ther. 2024;116:996–1004. https://doi.org/10.1002/cpt.3313.

Article  CAS  PubMed  Google Scholar 

Saadeddin A, Purohit V, Huh Y, Wong M, Maulny A, Dowty ME, et al. Virtual bioequivalence assessment of Ritlecitinib capsules with incorporation of observed clinical variability using a physiologically based pharmacokinetic model. AAPS J. 2024;26:17. https://doi.org/10.1208/s12248-024-00888-9.

Article  CAS  PubMed  Google Scholar 

Wada S, Kagatani S, Nakagami H. Quantitative estimation of intra-subject variability in bioequivalence studies of generic solid oral dosage forms by multiple regression analysis. J Drug Deliv Sci Technol. 2021;64:102656. https://doi.org/10.1016/j.jddst.2021.102656.

Article  CAS  Google Scholar 

Sugihara M, Takeuchi S, Sugita M, Higaki K, Kataoka M, Yamashita S. Analysis of intra- and intersubject variability in oral drug absorption in human bioequivalence studies of 113 generic products. Mol Pharm. 2015;12:4405–13. https://doi.org/10.1021/acs.molpharmaceut.5b00602.

Article  CAS  PubMed  Google Scholar 

Mohsen MA. A note on the calculation of intrasubject coeffi cient of variation in bioequivalence trails. J Bioanal Biomed. 2010;2:075–8. https://doi.org/10.4172/1948-593x.1000026.

Article  Google Scholar 

Chung I, Oh J, Lee S, Jang I-J, Lee Y, Chung J-Y. A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studies. Transl Clin Pharmacol. 2018;26:6–9. https://doi.org/10.12793/tcp.2018.26.1.6.

Article  PubMed  PubMed Central  Google Scholar 

Oh DM, Curl RL, Amidon GL. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res. 1993;10:264–70. https://doi.org/10.1023/a:1018947113238.

Article  CAS  PubMed  Google Scholar 

Piscitelli J, Hens B, Tomaszewska I, Wollenberg L, Litwiler K, McAllister M, et al. Effect of food and a proton-pump inhibitor on the absorption of Encorafenib: An In Vivo-In Vitro-In Silico Approach. Mol Pharm. 2023;20:2589–99. https://doi.org/10.1021/acs.molpharmaceut.3c00016.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li G, Wang K, Chen R, Zhao H, Yang J, Zheng Q. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. 2012;33:1359–71. https://doi.org/10.1038/aps.2012.103.

Article  CAS  Google Scholar 

Macwan JS, Fraczkiewicz G, Bertolino M, Krüger P, Peters S-A. Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: The case of bisoprolol. CPT: Pharmacometrics Syst Pharmacol. 2021;10:622–32. https://doi.org/10.1002/psp4.12634.

Wu X, Wang Z, Liu S, Wang H. Utilizing physiologically based pharmacokinetic models to support rational medication in Chinese elderly population. Drug Des Devel Ther. 2025;19:3077–101. https://doi.org/10.2147/dddt.s501143.

Article  PubMed  PubMed Central  Google Scholar 

Andreas CJ, Pepin X, Markopoulos C, Vertzoni M, Reppas C, Dressman JB. Mechanistic investigation of the negative food effect of modified release Zolpidem. Eur J Pharm Sci. 2017;102:284–98. https://doi.org/10.1016/j.ejps.2017.03.011.

Article  CAS  PubMed  Google Scholar 

Kollipara S, Sivadasu P, Rashmi S, Ravi PR, Guntupalli C. Role of physiologically based biopharmaceutics modeling in predicting and circumventing the drug-drug interactions of tyrosine kinase inhibitors with acid-reducing agents. J App Pharm Sci. 2025;15(6):055–69. https://doi.org/10.7324/japs.2025.234298.

Article  CAS  Google Scholar 

Saleem MT, Shoaib MH, Yousuf RI, Ahmed FR, Ahmed K, Siddiqui F, et al. SeDeM tool-driven full factorial design for osmotic drug delivery of tramadol HCl: Formulation development, physicochemical evaluation, and in-silico PBPK modeling for predictive pharmacokinetic evaluation using GastroPlusTM. Front Pharmacol. 2022;13: 974715. https://doi.org/10.3389/fphar.2022.974715.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smyj R, Wang X-P, Han F. Tramadol hydrochloride. Profiles of drug substances, excipients and related methodology. Elsevier; 2013. p. 463–94. https://doi.org/10.1016/b978-0-12-407691-4.00011-3.

Kuminek G, Salehi N, Waltz NM, Sperry DC, Greenwood DE, Hate SS, et al. Use of gastrointestinal simulator, mass transport analysis, and absorption simulation to investigate the impact of pH modifiers in mitigating weakly basic drugs’ performance issues related to gastric pH: palbociclib case study. Mol Pharm. 2022;20(1):147–58. https://doi.org/10.1021/acs.molpharmaceut.2c00545.

Article  CAS  PubMed  Google Scholar 

Dahan A, Porat D, Markovic M, Zur M, Kister O, Langguth P. Optimized in silico modeling of drug absorption after gastric bypass: The case of metformin. Pharmaceutics. 2021;13(11):1873. https://doi.org/10.3390/pharmaceutics13111873.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sagawa K, Purohit V, Le V, Hsu H-J, Ebrahimi E, Piscitelli J, et al. Development of a multi-purpose comprehensive physiologically based pharmacokinetic model for crizotinib: an example application in bioequivalence assessment between oral solution and granules in pediatric subjects. AAPS J. 2025;27:126. https://doi.org/10.1208/s12248-025-01106-w.

Article  CAS  PubMed  Google Scholar 

Guimarães M, Vertzoni M, Fotaki N. Performance evaluation of montelukast pediatric formulations: Part II—aPBPK modelling approach: evaluation of montelukast pediatric formulations: PBPK modelling. AAPS J. 2022;24(1):27. https://doi.org/10.1208/s12248-021-00662-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guimarães M, Vertzoni M, Fotaki N. Performance evaluation of Montelukast pediatric formulations: Part II - a PBPK modelling approach. AAPS J. 2022;24:27. https://doi.org/10.1208/s12248-021-00662-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luo T, Wang L, Ruan Z, Lou H, Yang D, Wang Z, et al. Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations. Clin Transl Sci. 2024;17:e13819. https://doi.org/10.1111/cts.13819.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gajewska M, Blumenstein L, Kourentas A, Mueller-Zsigmondy M, Lorenzo S, Sinn A, et al. Physiologically based pharmacokinetic modeling of oral absorption, pH, and food effect in healthy volunteers to drive alpelisib formulation selection. AAPS J. 2020;22:134. https://doi.org/10.1208/s12248-020-00511-7.

Article  CAS  PubMed  Google Scholar 

Cheng Z-Z, Hu X, Li Y-L, Zhang L. Predicting bioequivalence and developing dissolution bioequivalence safe space in vitro for warfarin using a physiologically-based pharmacokinetic absorption model. Eur J Pharm Biopharm. 2023;191:12–25. https://doi.org/10.1016/j.ejpb.2023.08.004.

Article  CAS  PubMed  Google Scholar 

Loisios-Konstantinidis I, Dressman J. Physiologically based pharmacokinetic/pharmacodynamic modeling to support waivers of in vivo clinical studies: current status, challenges, and opportunities. Mol Pharm. 2021;18:1–17. https://doi.org/10.1021/acs.molpharmaceut.0c00903.

Article  CAS